Last reviewed · How we verify
omeprazole/sodium bicarbonate
Omeprazole inhibits gastric acid secretion by blocking the proton pump in stomach parietal cells, while sodium bicarbonate provides rapid acid neutralization.
Omeprazole inhibits gastric acid secretion by blocking the proton pump in stomach parietal cells, while sodium bicarbonate provides rapid acid neutralization. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | omeprazole/sodium bicarbonate |
|---|---|
| Also known as | Zegerid, Zegerid Powder for Oral Suspension |
| Sponsor | Food and Drug Administration (FDA) |
| Drug class | Proton pump inhibitor with antacid |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Omeprazole is a proton pump inhibitor (PPI) that irreversibly binds to H+/K+-ATPase in the gastric mucosa, suppressing both basal and stimulated acid secretion. Sodium bicarbonate acts as a buffer to neutralize existing gastric acid immediately upon administration, providing rapid symptom relief while omeprazole's longer-acting mechanism takes effect over several days.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Acid-related dyspepsia
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Flatulence
Key clinical trials
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (PHASE2)
- Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) (PHASE2)
- Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill (PHASE3)
- Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets (PHASE1)
- A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects (PHASE1)
- A Unique Regimen for Treatment of Helicobacter Pylori Infection (PHASE3)
- Management of Myocardial Injury After Noncardiac Surgery Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- omeprazole/sodium bicarbonate CI brief — competitive landscape report
- omeprazole/sodium bicarbonate updates RSS · CI watch RSS
- Food and Drug Administration (FDA) portfolio CI